| First Author | McManus RM | Year | 2025 |
| Journal | Immunity | Volume | 58 |
| Issue | 2 | Pages | 326-343.e11 |
| PubMed ID | 39904338 | Mgi Jnum | J:365465 |
| Mgi Id | MGI:7869191 | Doi | 10.1016/j.immuni.2025.01.007 |
| Citation | McManus RM, et al. (2025) NLRP3-mediated glutaminolysis controls microglial phagocytosis to promote Alzheimer's disease progression. Immunity 58(2):326-343.e11 |
| abstractText | Activation of the NLRP3 inflammasome has been implicated in the pathogenesis of Alzheimer's disease (AD) via the release of IL-1beta and ASC specks. However, whether NLRP3 is involved in pathways beyond this remained unknown. Here, we found that Abeta deposition in vivo directly triggered NLRP3 activation in APP/PS1 mice, which model many features of AD. Loss of NLRP3 increased glutamine- and glutamate-related metabolism and increased expression of microglial Slc1a3, which was associated with enhanced mitochondrial and metabolic activity. The generation of alpha-ketoglutarate during this process impacted cellular function, including increased clearance of Abeta peptides as well as epigenetic and gene transcription changes. This pathway was conserved between murine and human cells. Critically, we could mimic this effect pharmacologically using NLRP3-specific inhibitors, but only with chronic NLRP3 inhibition. Together, these data demonstrate an additional role for NLRP3, where it can modulate mitochondrial and metabolic function, with important downstream consequences for the progression of AD. |
